BiotechTube
OncoC4

OncoC4

Rockville, United States· Est.
oncoc4.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $160M

Overview

OncoC4 is a private, clinical-stage biotech focused on novel immuno-oncology and neurodegenerative disease therapeutics. Its core strategy involves targeting both established (CTLA-4, PD-1) and emerging (CD24, Siglec) immune checkpoints with a pipeline of monoclonal antibodies, bispecifics, and antibody-drug conjugates. The company has established a key partnership with BioNTech for its lead CTLA-4 asset and operates with a lean, global team. OncoC4 is positioned in the competitive but high-potential fields of next-generation cancer immunotherapy and neuro-immunology.

OncologyNeurodegenerative Diseases

Technology Platform

Multi-target immune checkpoint platform focusing on CTLA-4, PD-1/VEGF, Siglec, and CD24 pathways for developing monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates for cancer and Alzheimer's disease.

Funding History

3
Total raised:$160M
PIPE$50M
Series B$80M
Series A$30M

Opportunities

The partnership with BioNTech on the lead CTLA-4 asset provides validation, funding, and development expertise for a late-stage program in a high-need oncology population.
Successfully developing a tumor-selective anti-CD24 antibody could address approximately 70% of human cancers, representing a massive, novel market opportunity.

Risk Factors

The company faces high clinical development risk, particularly for its novel Siglec program in Alzheimer's disease, a field with a high failure rate.
Intense competition in the immuno-oncology space from larger, well-resourced companies poses a significant commercial threat to its next-generation CTLA-4 and PD-1/VEGF candidates.

Competitive Landscape

OncoC4 competes in the crowded next-generation immuno-oncology space against large pharma (e.g., BMS, Merck, Roche/Astellas) and numerous biotechs. Its differentiation hinges on improved safety profiles and efficacy in resistant settings. In the novel CD24 and neuro-immunology (Siglec) spaces, competition is less crowded but scientifically riskier, competing against other early-stage biotechs and academic efforts.

More companies in United States →